Single-Dose Nirsevimab Provides Season-Long RSV Protection for Preterm Infants
Single-dose nirsevimab successfully reduced rates of respiratory syncytial virus-associated lower respiratory infections and hospitalizations in pre-term infants.
Single-dose nirsevimab successfully reduced rates of respiratory syncytial virus-associated lower respiratory infections and hospitalizations in pre-term infants.
Results are provided within 15 minutes and can be read directly from the testing card.
Current guidelines from Italy, the UK, and China do not focus on screening patients for anosmia as a potential symptom for COVID-19.
Researchers found limited clinical variability between PIV serotypes and substantial overlap in presenting signs and symptoms for PIV and other etiologies.
Following the initial pandemic wave of SARS-CoV-2 infections, it is unclear what trajectory of transition SARS-CoV-2 might take.
Study results may provide guidance for healthcare policy and pandemic management at a selective, local level.
Children aged <5 years were found to have significantly greater levels of SARS-CoV-2 viral nucleic acid compared with older children and adults.
Dr. Razzaghi and colleagues estimated the county-level prevalence of selected conditions associated with severe COVID-19.
In immunocompromised adults, community-acquired pneumonia should be treated by a multidisciplinary team of physicians.
The observational study, which was led by the Albert Einstein College of Medicine and Montefiore Health System, aimed to assess the effect of glucocorticoid therapy on mortality and the need for mechanical ventilation in hospitalized patients with COVID-19.